UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/612,491	07/01/2003	Vahid Saadat	USGINZ02112	3557
	7590 05/26/200 ADE HAN LLP	9	EXAMINER	
2400 GENG ROAD, SUITE 120			YABUT, DIANE D	
PALO ALTO, CA 94303			ART UNIT	PAPER NUMBER
			3734	
			MAIL DATE	DELIVERY MODE
			05/26/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)		
	10/612,491	SAADAT ET AL.		
Office Action Summary	Examiner	Art Unit		
	DIANE YABUT	3734		
The MAILING DATE of this communication a Period for Reply	ppears on the cover sheet with th	ne correspondence address		
A SHORTENED STATUTORY PERIOD FOR REF WHICHEVER IS LONGER, FROM THE MAILING - Extensions of time may be available under the provisions of 37 CFR after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period. - Failure to reply within the set or extended period for reply will, by stal Any reply received by the Office later than three months after the ma earned patent term adjustment. See 37 CFR 1.704(b).	DATE OF THIS COMMUNICAT 1.136(a). In no event, however, may a reply bod will apply and will expire SIX (6) MONTHS tute, cause the application to become ABANDO	ION. be timely filed from the mailing date of this communication. DNED (35 U.S.C. § 133).		
Status				
Responsive to communication(s) filed on <u>02</u> This action is FINAL . 2b) ☐ TI Since this application is in condition for allow closed in accordance with the practice unde	nis action is non-final. vance except for formal matters,			
Disposition of Claims				
4) ☐ Claim(s) 1-7,9,16,26,27 and 32-40 is/are pe 4a) Of the above claim(s) is/are withd 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) 1-7,9,16,26,27 and 32-40 is/are rej 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) are subject to restriction and Application Papers 9) ☐ The specification is objected to by the Exami	rawn from consideration. ected. d/or election requirement.			
10) The drawing(s) filed on is/are: a) a Applicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the	ccepted or b) objected to by the drawing(s) be held in abeyance. ection is required if the drawing(s) is	See 37 CFR 1.85(a). objected to. See 37 CFR 1.121(d).		
Priority under 35 U.S.C. § 119				
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 				
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summ Paper No(s)/Ma 5) Notice of Inform 6) Other:			

Art Unit: 3734

DETAILED ACTION

1. In view of the appeal brief filed on 02/02/2009, PROSECUTION IS HEREBY

REOPENED. New grounds of rejection are set forth below.

To avoid abandonment of the application, appellant must exercise one of the following

two options:

(1) file a reply under 37 CFR 1.111 (if this Office action is non-final) or a reply under 37

CFR 1.113 (if this Office action is final); or,

(2) initiate a new appeal by filing a notice of appeal under 37 CFR 41.31 followed by an

appeal brief under 37 CFR 41.37. The previously paid notice of appeal fee and appeal brief fee

can be applied to the new appeal. If, however, the appeal fees set forth in 37 CFR 41.20 have

been increased since they were previously paid, then appellant must pay the difference between

the increased fees and the amount previously paid.

A Supervisory Patent Examiner (SPE) has approved of reopening prosecution by signing

below:

/Todd E Manahan/

Supervisory Patent Examiner, Art Unit 3734

Art Unit: 3734

Claim Rejections - 35 USC § 112

2. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 1-5 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

3. Claim 1 recites the limitation "the tissue fold" in the last line. There is insufficient antecedent basis for this limitation in the claim.

Claim Rejections - 35 USC § 102

4. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371(c) of this title before the invention thereof by the applicant for patent.

The changes made to 35 U.S.C. 102(e) by the American Inventors Protection Act of 1999 (AIPA) and the Intellectual Property and High Technology Technical Amendments Act of 2002 do not apply when the reference is a U.S. patent resulting directly or indirectly from an international application filed before November 29, 2000. Therefore, the prior art date of the reference is determined under 35 U.S.C. 102(e) prior to the amendment by the AIPA (pre-AIPA 35 U.S.C. 102(e)).

5. <u>Claims 39-40</u> are rejected under 35 U.S.C. 102(e) as being anticipated by **Adams et al.** (U.S. Patent No. **6,736,828**).

Adams et al. disclose moving a catheter 16 into a patient, holding a tissue fold 14 within the patient with a tissue grasper 18, extending a piercing element 40 from the catheter through the tissue fold, moving a first anchor (one end of element 42) out from the piercing element on a first side 46 of the tissue fold, withdrawing the piercing element from the tissue fold, moving a second anchor (the other end of element 42) out from the piercing element on a second side 44 of the tissue fold, and holding the tissue fold via a connection element 42 connecting the first and second anchors (Figures 1 and 5-7).

Claim Rejections - 35 USC § 103

- 6. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
 - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 7. <u>Claims 1-2, 5-7, 9, 16, 26, and 32-38</u> are rejected under 35 U.S.C. 103(a) as being unpatentable over **Adams et al.** (U.S. Patent No. **6,736,828**) in view of **Saadat** (U.S. Patent No. **7,186,262**).

Adams et al. disclose providing a delivery catheter or endoscope 16 having a needle 40 translatably disposed therein, a distal end, a stabilization device 18 disposed at the distal end

Application/Control Number: 10/612,491

Art Unit: 3734

holding a tissue fold 14, one or more anchors (either end of element 42) disposed within the needle, advancing the delivery catheter into the gastroesophageal junction, engaging the stabilization device to a tissue wall of

the gastroesophageal junction, advancing the needle through the catheter and a first tissue wall 46 and a second tissue wall 44, ejecting anchors (ends of element 42) from a distal tip of the needle, the anchors having a suture or connection element 42 attached thereto, withdrawing the needle from the tissue walls whereby the suture is extended through the tissue walls and the first and second anchors are placed on either side of the tissue walls to maintain the tissue fold (see abstract, Figures 1 and 5-7).

Although a gastroesophageal junction is accessed instead of tissue walls of a gastrointestinal lumen to create a tissue fold, it would have been obvious to one of ordinary skill in the art to apply the fundoplication method of Adams et al. to gastrointestinal tissue since it was well known in the art to manipulate gastric tissue by fundoplication to reduce the area of a gastrointestinal lumen for aiding obese patients in managing the amount of food desired and eaten.

Adams et al. also lacks translation of a fastener over the suture whereby a tension force is created on the suture and the tissue fold is maintained, wherein the fastener has collar through which the suture extends.

Saadat teaches translating a fastener **532** comprising a collar with a central channel through which a suture **506** extends whereby a tension force is created on the suture and said tissue fold is maintained (Figure 49A; col. 24, lines 42-51). It would have been obvious to one of ordinary skill in the art to modify Adams et al. by replacing the anchors and connecting

Art Unit: 3734

element **42** with a suture fastener or crimp with a channel, as taught by Saadat, so that the tension is maintained and the fastener may be translated over the suture after the tissue has been approximated to adjust tension.

8. <u>Claim 3</u> is rejected under 35 U.S.C. 103(a) as being unpatentable over **Adams et al.** (U.S. Patent No. 6,736,828) in view of **Saadat** (U.S. Patent No. 7,186,262), as applied to claim 1 above, and further in view of **Koike et al.** (U.S. Patent No. 6,056,760).

Adams et al. and Saadat disclose the claimed invention except for ejecting the anchor from the distal tip of the needle by translating a push rod disposed in the needle.

Koike et al. teach ejecting an anchor from a distal tip of the needle comprising translating a push rod 3 disposed in the needle (Figures 1 and 7 and col. 4, lines 58-67). It would have been obvious to one of ordinary skill in the art at the time of invention to provide a push rod to eject the anchors, as taught by Koike et al., to Adams et al. and Saadat to facilitate advancement and positioning of the anchors.

9. <u>Claim 4</u> is rejected under 35 U.S.C. 103(a) as being unpatentable over **Adams et al.** (U.S. Patent No. 6,736,828) in view of **Saadat** (U.S. Patent No. 7,186,262), as applied to claim 1 above, and further in view of **Laufer et al.** (U.S. Pub. No. 2004/0194790).

Adams et al. and Saadat disclose the claimed invention except for the stabilization device being a coil with a sharpened tip and rotating the coil to engage the coil into the tissue wall.

Laufer et al. teach a stabilization device **740** disposed at the distal end comprising a coil **740**, or tissue holding element, having a sharpened tip and engaging the stabilization device to

Art Unit: 3734

the tissue wall by rotating the coil (Figure 4A and page 3, paragraphs 79 and 83). It would have been obvious to one of ordinary skill in the art to provide a rotating coil stabilization device, as taught by Laufer et al., to Adams et al. and Saadat to facilitate engagement with tissue as the coil is biased in a distal direction to urge against tissue (page 1, paragraph 7).

10. <u>Claim 27</u> is rejected under 35 U.S.C. 103(a) as being unpatentable over **Adams et al.** (U.S. Patent No. **6,736,828**) in view of **Saadat** (U.S. Patent No. **7,186,262**), as applied to claim 26 above, and further in view of **Gannoe et al.** (U.S. Patent No. **6,746,460**).

Adams et al. and Saadat disclose the claimed invention, including creating a tissue fold, except for creating a second tissue fold on an opposing tissue wall.

Gannoe et al. teach providing creating a second tissue fold on an opposing tissue wall (Figure 5A and col. 5, lines 23-37). It would have been obvious to one of ordinary skill in the art to provide a second tissue fold, as taught by Gannoe et al., to Adams et al. and Saadat since providing a multitude of folds depends on the desired results and the anchoring configuration or to facilitate further approximation of multiple sections tissue.

Response to Arguments

11. Applicant's arguments with respect to claims 1-7, 9, 16, 26-27, and 32-40 have been considered but are moot in view of the new ground(s) of rejection.

Art Unit: 3734

Conclusion

Any inquiry concerning this communication or earlier communications from the

examiner should be directed to DIANE YABUT whose telephone number is (571)272-6831.

The examiner can normally be reached on M-F: 9AM-4PM EST.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Todd Manahan can be reached on (571) 272-4713. The fax phone number for the

organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent

Application Information Retrieval (PAIR) system. Status information for published applications

may be obtained from either Private PAIR or Public PAIR. Status information for unpublished

applications is available through Private PAIR only. For more information about the PAIR

system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR

system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would

like assistance from a USPTO Customer Service Representative or access to the automated

information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Diane Yabut/

Examiner, Art Unit 3734

/Todd E Manahan/

Supervisory Patent Examiner, Art Unit 3734